The pharma ADMET testing market in Middle East & Africa is expected to grow from US$ 270.94 million in 2022 to US$ 437.71 million by 2028. It is estimated to grow at a CAGR of 8.3% from 2022 to 2028.

The disaster of a rising number of therapeutic molecules in the last phases of clinical trials has cost money and valuable time invested in developing new drugs. This has led to higher investments being made in the development of fresher technology for toxicity testing. According to the article “Importance of ADME/Tox in Early Drug Discovery, ” 2022, in the current drug discovery and development pipeline, only 10 molecules out of 1,000 screened hits are projected to enter the preclinical testing stage, and only 9.6% will enter clinical trials.

The drug approval process is projected to take 15 years on an average, and phases II and III are the most expensive phases of clinical trials. According to the study titled “Why 90% of Clinical Drug Development Fails and How to Improve It?”, 2022, 90% of clinical drug development fails despite implementing many strategies. After entering clinical investigations, 9 out of 10 drug candidates fail during phase I, II, and III clinical trials and the drug approval process. Drug candidates rejected in preclinical stages are not included in the 90% failure rate of the drugs in clinical stages, as they do not enter the phase I clinical trials. If preclinical drug candidates are included, the drug discovery and development failure rate rise even higher than 90%. According to analyses of clinical trial data from 2010 to 2017, lacking clinical effectiveness (40–50%), uncontrollable toxicity (30%), poor drug-like qualities (10–15%), no commercial needs, and ineffective strategic planning (10%) are the four major causes of trial failure. New drug development is both resource and time-intensive, where later clinical stages result in high costs.

To lower the attrition rate in drug research & development, it is crucial to filter and optimize the absorption, distribution, metabolism, elimination, and toxicity (ADMET) characteristics of pharmaceuticals at an early stage. It has been widely accepted that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. In vitro and in vivo drug evaluation techniques have reached maturity in preclinical applications, and in silico technologies are gaining vast acceptance to evaluate the relevant properties of drugs in the preclinical stage. The development of software programs and in silico models is further promoting the implementation of ADMET studies. Thus, the increasing need for drug-development ADME testing boosts the pharma ADMET testing market .

Middle East & Africa Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Pharma ADMET Testing Market Segmentation

The Middle East & Africa pharma ADMET testing market is segmented by testing type, technology, application, and country. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment is dominating the market in 2022. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment is dominating the market in 2022. Based on application, the market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment is dominating the market in 2022. Based on country, the market is segmented intoSouth Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa. Further, South Africa dominated the market in 2022.

A few key players dominating the Middle East & Africa pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; IQVIA Inc.; MERCK KGaA; Promega Corporation; and Wuxi AppTec.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Pharma ADMET Testing Market – By Testing Type
1.3.2 MEA Pharma ADMET Testing Market – By Technology
1.3.3 MEA Pharma ADMET Testing Market – By Application
1.3.4 MEA Pharma ADMET Testing Market – By Country
2. MEA Pharma ADMET Testing Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Pharma ADMET Testing Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 MEA – PEST Analysis
4.3 Expert Opinion
5. Pharma ADMET Testing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Rate of Late-Stage Drug Failure
5.1.2 Increasing Number of Product Approvals and Launches
5.2 Market Restraints
5.2.1 High Cost of ADME Testing Studies
5.3 Market Opportunities
5.3.1 Automation and Advancements in ADME Testing
5.4 Future Trends
5.4.1 The Advent of High-Throughput Screening
5.5 Impact Analysis
6. Pharma ADMET Testing Market– MEA Analysis
6.1 MEA Pharma ADMET Testing Market Revenue Forecast and Analysis
7. MEA Pharma ADMET Testing Market– By Testing Type
7.1 Overview
7.2 MEA Pharma ADMET Testing Market, By Testing Type 2022 & 2028 (%)
7.3 In Vivo ADMET Testing
7.3.1 Overview
7.3.2 In Vivo ADMET Testing – Revenue and Forecast to 2028 (US$ Million)
7.4 In Vitro ADMET Testing
7.4.1 Overview
7.4.2 In Vitro ADMET Testing – Revenue and Forecast to 2028 (US$ Million)
7.5 In Silico ADMET Testing
7.5.1 Overview
7.5.2 In Silico ADMET Testing – Revenue and Forecast to 2028 (US$ Million)
8. MEA Pharma ADMET Testing Market– By Technology
8.1 Overview
8.2 MEA Pharma ADMET Testing Market, By Technology 2022 & 2028 (%)
8.3 Cell Culture
8.3.1 Overview
8.3.2 Cell Culture – Market Revenue and Forecast to 2028 (US$ Million)
8.4 High Throughput
8.4.1 Overview
8.4.2 High Throughput – Market Revenue and Forecast to 2028 (US$ Million)
8.5 Molecular Imaging
8.5.1 Overview
8.5.2 Molecular Imaging – Market Revenue and Forecast to 2028 (US$ Million)
8.6 OMICS Technology
8.6.1 Overview
8.6.2 OMICS Technology – Market Revenue and Forecast to 2028 (US$ Million)
9. MEA Pharma ADMET Testing Market– By Application
9.1 Overview
9.2 MEA Pharma ADMET Testing Market, By Application 2022 & 2028 (%)
9.3 Systemic Toxicity
9.3.1 Overview
9.3.2 Systemic Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
9.4 Renal Toxicity
9.4.1 Overview
9.4.2 Renal Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
9.5 Hepatotoxicity
9.5.1 Overview
9.5.2 Hepatotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
9.6 Neurotoxicity
9.6.1 Overview
9.6.2 Neurotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others – Revenue And Forecasts to 2028 (US$ Million)
10. MEA Pharma ADMET Testing Market– Country Analysis
10.1 MEA: Pharma ADMET Testing Market
10.1.1 Overview
10.1.2 MEA Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)
10.1.2.1 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.1.3 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.1.4 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.2.1.5 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.2.2 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.2.3 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.2.4 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.2.2.5 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.2.3 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 South Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.3.3 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Technology (US$ Million)
10.1.2.3.5 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.2.4 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.4.1 Overview
10.1.2.4.2 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.4.3 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.4.4 Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.2.4.5 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
11. MEA Pharma ADMET Testing Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Charles River Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 WuXi AppTec
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Promega Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sigma-Aldrich (MERCK KGaA)
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Agilent Technologies, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Biovia (Dassault Systèmes)
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 IQVIA Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms

LIST OF TABLES

Table 1.             MEA Pharma ADMET Testing Market –Revenue and Forecast to 2028 (US$ Million)
Table 2.             UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 3.             UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 4.             UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 5.             Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 6.             Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 7.             Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 8.             South Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 9.             South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 10.          South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 11.          Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 12.          Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 13.          Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 14.          Organic Developments Done by Companies
Table 15.          Inorganic Developments Done by Companies
Table 16.          Glossary of Terms
 
 

LIST OF FIGURES

Figure 1.           MEA Pharma ADMET Testing Market Segmentation
Figure 2.           MEA Pharma ADMET Testing Market, By Country
Figure 3.           MEA Pharma ADMET Testing Market Overview
Figure 4.           In vivo ADMET Testing Segment Held Largest Share of Testing Type Segment in MEA Pharma ADMET Testing Market
Figure 5.           South Africa is Expected to Show Remarkable Growth During the Forecast Period
Figure 6.           MEA: PEST Analysis
Figure 7.           Expert Opinion
Figure 8.           MEA Pharma ADMET Testing Market Impact Analysis of Driver and Restraints
Figure 9.           MEA Pharma ADME Testing Market– Revenue Forecast and Analysis – 2022 – 2028
Figure 10.        MEA Pharma ADMET Testing Market, by Testing Type 2022 & 2028 (%)
Figure 11.        In Vivo ADMET Testing – Revenue and Forecasts to 2028 (US$ Million)
Figure 12.        In Vitro ADMET Testing – Revenue and Forecasts to 2028 (US$ Million)
Figure 13.        In Silico ADMET Testing – Revenue and Forecasts to 2028 (US$ Million)
Figure 14.        MEA Pharma ADMET Testing Market, by Technology 2022 & 2028 (%)
Figure 15.        Cell Culture – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16.        High Throughput – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17.        Molecular Imaging – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18.        OMICS Technology – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19.        MEA Pharma ADMET Testing Market, by Application 2022 & 2028 (%)
Figure 20.        Systemic Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21.        Renal Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22.        Hepatotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
Figure 23.        Neurotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
Figure 24.        Others – Revenue And Forecasts to 2028 (US$ Million)
Figure 25.        MEA Pharma ADMET Testing Market Revenue Overview, by Country, 2022 (US$ Million)
Figure 26.        MEA Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)
Figure 27.        UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28.        Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29.        South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30.        Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa pharma ADMET testing market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharma ADMET testing market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the pharma ADMET testing market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

The List of Companies – Middle East & Africa Pharma ADMET Testing Market

● Agilent Technologies, Inc.
● Bio-Rad Laboratories, Inc.
● Biovia (Dassault Systèmes)
● Charles River Laboratories
● IQVIA Inc.
● MERCK KGaA
● Promega Corporation
● Wuxi AppTec

At 8.3% CAGR, the Middle East & Africa pharma ADMET testing market is speculated to be worth US$ 437.71 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Middle East & Africa pharma ADMET testing market was valued at US$ 270.94 million in 2022 and is expected to reach US$ 437.71 million by 2028, registering an annual growth rate of 8.3% from 2022 to 2028. The advent of high-throughput screening and high rate of late-stage drug failure are the critical factors attributed to the market expansion.

Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that have the potential to rapidly improve medicines available on market. In the last 10 years, the influence of AI and Big Data analytics on disease diagnosis and treatment, and a shift toward preventing life-threatening conditions rather than curing them have led to the evolution of healthcare. With the continuous evolution of science and technology, exciting developments in the field of high throughput ADME (HT-ADME) research are highly anticipated in the next decade. The emerging fields of ADME sciences will find their way into ADME screening studies from the perspective of the assay repertoire. The novel, physiologically appropriate in vitro micro physiological systems (MPS), such as 3D tissue cultures and organ(s)-on-a-chip, are likely to make their way in the improvement efforts for in vitro in vivo translation (IVIVT). The use of endogenous probes (basic biomarkers) for in vivo transporter drug-drug interaction (DDI) investigations is coming up as another trend in ADME testing, as this approach can lower pill burden and help obtain transporter DDI data from a standard phase I trial. The HT-ADME screening of innovative drug delivery systems is yet another example. The field is prepared to undertake early ADME screening of novel modalities, such as protein degraders, antisense oligonucleotides (ASOs), antibody-drug conjugates (ADCs), and biologics, in addition to small molecules and peptides. Although the ADME studies for these modalities are still in the developing stage, an increasing number of HT-ADME format assays are anticipated to go online to support ongoing scientific research. With the long history of HT-ADME operation in many companies and the resulting wealth of ADME data that can be “mined”, the development of in silico models to predict ADME properties has long been acknowledged as the obvious next step for HT-ADME screening. The HT-ADME dataset of any big pharmaceutical company could include test findings from numerous compounds, in contrast to many ADME prediction models described in the literature that employ a training set of a smaller number of compounds. Due to their size, these datasets can prove to be the best training sets for model building. ADME features have long been studied using computational chemistry methods designed to create quantitative structure-activity relationship (QSAR) models. Models for clearance, permeability, and DDI potentials have recently been developed using various machine learning (ML) techniques. Hit triaging from lead discovery screens and the design-make-test cycles of lead optimization in drug discovery, among others, can be employed to obtain predictive ADME models due to the recent rapid developments in ML methodologies and the large size of the HT-ADME datasets available for use as training sets. These top trends will transform the pharmaceutical industry and can have short-term and long-term benefits on the ADMET testing market.

On the contrary, high cost of ADME testing studies hurdles the growth of Middle East & Africa pharma ADMET testing market.

Based on testing type, the Middle East & Africa pharma ADMET testing market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment held 52.7% market share in 2022, amassing US$ 142.75 million. It is projected to garner US$ 229.60 million by 2028 to expand at 8.2% CAGR during 2022–2028.

Based on technology, the Middle East & Africa pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment held 43.1% market share in 2022, amassing US$ 116.73 million. It is projected to garner US$ 189.92 million by 2028 to expand at 8.5% CAGR during 2022–2028.

By the application, the Middle East & Africa pharma ADMET testing market is fragmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. With 70.8% share of the domain, the systemic toxicity segment dominated the market in 2022. It accrued US$ 191.75 million in 2022 and is estimated to generate US$ 311.76 million by 2028 to grow at a CAGR of 8.4% over the forecast period.

Based on country, the Middle East & Africa pharma ADMET testing market is categorized into South Africa, Saudi Arabia, the UAE, and the rest of Middle East & Africa. Our regional analysis states that South Africa captured 35.9% market share in 2022. It was assessed at US$ 97.29 million in 2022 and is likely to hit US$ 155.28 million by 2028, exhibiting a CAGR of 8.1% during the forecast period.

Key players dominating the Middle East & Africa pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; MERCK KGaA; Promega Corporation; and Wuxi AppTec among others.